Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00272181 · ClinicalTrials.gov registry record · Phase 2
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase 2 study, sponsored by Sesen Bio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00272181 is a Phase 2 study that was terminated before completion, run by Sesen Bio. The registered enrollment target is 15 participants.
The verdict
NCT00272181, a Phase 2 study, was terminated before completion, sponsored by Sesen Bio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, effectiveness, and recommended dose of Proxinium in North American patients with Squamous Cell Head and Neck Cancer
Interventions
- DRUG Proxinium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00272181
The ClinicalTrials.gov registry entry for NCT00272181 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sesen Bio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Proxinium is the first listed.
NCT00272181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00272181 about?
NCT00272181 is a clinical study titled "Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer". The purpose of this study is to determine the safety, effectiveness, and recommended dose of Proxinium in North American patients with Squamous Cell Head and Neck Cancer
What is the current status of trial NCT00272181?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2006-01. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00272181?
The interventions under investigation include: Proxinium (DRUG).
Who is sponsoring clinical trial NCT00272181?
This trial is sponsored by Sesen Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.